Investor Overview

Corporate Profile
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational product using CODIT™, AR101 for the treatment of peanut allergy, has... more >
Recent Newsmore >
May 11, 2017
Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
— “Real-World” Trial Will Augment Ongoing Phase 3 PALISADE Trial to Support Regulatory Filings and Market Understanding — BRISBANE, Calif.--(BUSINESS WIRE)--May 11, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the enrollment of its first patient in the Phase 3 RAMSES (ARC007) clinical trial of AR101 for treatment of peanut allergy. AR101 is Aimmune’s investigational biologic oral immunotherapy for desensitization of patient... 
May 9, 2017
Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16
BRISBANE, Calif.--(BUSINESS WIRE)--May 9, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will present a company overview at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on Tuesday, May 16, at 1:00 p.m. Pacific Time. ... 
May 8, 2017
Aimmune Therapeutics Announces First Quarter 2017 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--May 8, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced financial results for first quarter 2017. As of March 31, 2017, cash, cash equivalents and investments totaled $259.3 million. “We continue to be very pleased with progress in PALISADE, our ... 
Upcoming Eventsmore >
There are currently no events scheduled.
Email Alerts
Sign up to receive email alerts when Aimmune Therapeutics posts new information to this site. Please enter your email address and click submit below.